What the semaglutide 7.2 mg clinical trial evidence actually shows

You were reading about Wegovy results and kept seeing two different numbers

Fifteen percent. Then twenty. You'd come across articles about a "higher dose" and wondered whether the original Wegovy studies were already out of date. They're not, but context matters here.

The landmark STEP 1 trial, published in the New England Journal of Medicine, established what 2.4 mg weekly semaglutide could do: roughly 15% average weight loss over 68 weeks in adults with obesity or overweight and at least one weight-related condition. That remains the bedrock of the evidence base for Wegovy. What changed in early 2026 was the arrival of a higher maintenance dose (7.2 mg) and the trial data supporting it.

The 7.2 mg programme showed average weight loss of around 20.7% at 72 weeks. That's a meaningful step up. It also begins to close the gap with tirzepatide, a point the Wegovy clinical trial results page explores in more detail. Worth noting: the trial was conducted in adults with a BMI of 30 or above. The 7.2 mg licence does not extend to the lower BMI band (27–29.9 with a comorbidity) that the 2.4 mg dose covers.

What the MHRA approved, and how the single-dose pen fits into the picture

On 12 January 2026, the MHRA approved semaglutide 7.2 mg as a licensed weight-management dose in the UK. At that point it was supplied as three 2.4 mg pens used in a single week, workable, but not exactly convenient if you keep your pen in the fridge door and like a simple routine.

That changed on 14 April 2026, when the MHRA approved a dedicated single-dose 7.2 mg pen: one pre-set injection per week, built-in covered needle, locks after use. The pen confirmed what the clinical programme had already suggested, this was a meaningful addition to licensed options, not a workaround. You can read the official announcement on GOV.UK.

Titration still starts at 0.25 mg, regardless of which maintenance dose you're heading towards. The prescriber sets the pace of dose increases; 7.2 mg is the ceiling, not the starting point. If you're already established on 2.4 mg weekly injections and clinically suitable, your prescriber may consider moving up, but that's a clinical conversation, not something to arrange independently. For a broader look at the trials behind the Wegovy licence, there's dedicated coverage on that page.

How the 7.2 mg results sit alongside the wider semaglutide evidence

The STEP 1 figure of ~15% and the 7.2 mg figure of ~20.7% are not directly comparable in the way a head-to-head trial would be, different populations, different durations, different trial designs. That's worth saying plainly. What the 7.2 mg data does show is a dose-response pattern that was already emerging in earlier semaglutide work: more drug, more effect on appetite and weight, within the licensed range.

For context, the Wegovy clinical trials page covers the full STEP programme. SURMOUNT-5, the head-to-head trial published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4 mg, and tirzepatide produced greater average weight loss. The 7.2 mg dose narrows that gap, though no head-to-head trial against tirzepatide at 7.2 mg has reported yet. NICE's appraisal of semaglutide (TA875) was based on the 2.4 mg evidence; a formal NICE review of 7.2 mg had not been published at the time of writing.

Side effects at 7.2 mg follow the same gastrointestinal profile as the 2.4 mg dose (nausea, vomiting, diarrhoea, constipation) generally most noticeable after starting or a step up, and often settling within a couple of weeks. Any new or persistent symptoms are worth raising with your prescriber promptly.

For a look at how Wegovy pricing compares across UK providers, that page covers the practical cost picture without the marketing noise.

What this means if you're considering treatment

The 7.2 mg approval gives prescribers a stronger option for adults with obesity who are responding well to semaglutide at lower doses but want more. It's a licensed medicine, available on private prescription from a GPhC-registered pharmacy, assessed on clinical grounds each time. It is not available on the NHS pending a NICE appraisal; stock availability of specific dose formats is something a prescriber can confirm at consultation.

A prescriber reviews the full picture, your health history, current medicines, BMI, and whether the evidence supports treatment for you specifically. The trial data is part of that picture. It's a good reason to ask the question. Check your eligibility with our prescribers and get a same-day clinical review at no cost.